There is one clinical trial.
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Description: Total number of grade 3 and above throughout study periodMeasure: Cumulative incidence of serious adverse events related to the treatment intervention. Time: up to 60 days post-transfusion
Description: All cause mortality at day 28Measure: Mortality at Day 28 post-hospital admission. Time: up to 28 days post-transfusion
Description: Total number of days subjects are hospitalized during study periodMeasure: Length of hospital stay Time: up to 60 days post-transfusion
Description: Total number of days subjects requires supplemental oxygen during study periodMeasure: Length of supplemental oxygen requirement. Time: up to 60 days post-transfusion
Description: Total number of days subjects require mechanical ventilation during study periodMeasure: Length of mechanical ventilation requirement. Time: up to 60 days post-transfusion
Description: Total number of days subject is subject stays in the ICUMeasure: Length of ICU stay Time: up to 60 days post-transfusion
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports